colchicine
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
6919
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
December 13, 2025
RECLAIM Adaptive Platform Trial for PCC Treatments
(clinicaltrials.gov)
- P3 | N=1250 | Enrolling by invitation | Sponsor: Janneke van de Wijgert
New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 13, 2025
The Association Between Takotsubo Cardiomyopathy and Acute Pericarditis.
(PubMed, JACC Case Rep)
- "This case illustrates the rare Takotsubo cardiomyopathy-pericarditis association and emphasizes the diagnostic value of advanced imaging for accurate management."
Journal • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Heart Failure • Inflammation • Pain
November 04, 2025
MEFV E148Q-P369S-R408Q germ line variant identified from the adolescent imcd-tafro family conferred severe disease manifestations in a cohort of 37 patients with castleman disease
(ASH 2025)
- "The siltuximab-based anti-IL-6 regimen demonstrated promising clinicalefficacy, with the patient maintaining complete remission for 36 months of follow-up at the time ofAbstract preparation.Using WES, we identified Mediterranean fever (MEFV) E148Q-P369S-R408Q germ line variant in thepatient, inherited from his asymptomatic parents. Our study adds to the very limited literature by describing the genomic characteristics of anadolescent TAFRO and the high responsiveness to anti-IL-6 based therapy. MEFV E148Q-P369S-R408Qgerm line variant was identified and appeared to be potent in promoting inflammation induced by LPS,which was partly abrogated by colchicine in vitro. ScRNA-seq revealed that MEFV-enriched CD16+monocytes interacted with naïve B/memory B cells, contributing to IL-6 pathway activation."
Clinical • Hematological Disorders • Inflammation • Myelofibrosis • Rare Diseases • Thrombocytopenia • IL1B
December 12, 2025
Acute pericarditis after ovarian stimulation in a patient with systemic lupus erythematosus: a case report and literature review.
(PubMed, Front Immunol)
- "Significant clinical improvement was observed following treatment with glucocorticoids, colchicine, and immunosuppressive agents. A literature review identified eight additional cases of SLE flares following ovarian stimulation, presenting with arthritis, rash, pericarditis, nephritis, or thrombotic events. Consequently, a comprehensive recurrence risk assessment and close monitoring of disease activity are recommended for SLE patients undergoing this fertility treatment."
Journal • Review • Cardiovascular • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Nephrology • Pain • Rheumatology • Systemic Lupus Erythematosus
December 12, 2025
P048 Lenalidomide use in recalcitrant inflammatory dermatoses: a trio of successes.
(PubMed, Br J Dermatol)
- "A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses."
Journal • Cardiovascular • Cataract • Dental Disorders • Dermatology • Discoid Lupus Erythematosus • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lupus • Lymphoma • Movement Disorders • Multiple Myeloma • Myelodysplastic Syndrome • Neutropenia • Oncology • Ophthalmology • Pain • Peripheral Neuropathic Pain • Rheumatology • Stomatitis • Systemic Lupus Erythematosus • Thrombocytopenia • IL12A • IL6
December 12, 2025
CD03 Heavy is the crown: hidden allergy in dental restorations.
(PubMed, Br J Dermatol)
- "Colchicine was trialled but subsequently discontinued due to intolerable side-effects...This case raises awareness of bornanedione and highlights a delayed reaction to this rare contact allergen. This is an important consideration for all doctors and dentists particularly in the context of a nationwide rise in cosmetic dentistry."
Journal • Allergy • Anesthesia • Immunology • Mood Disorders
December 12, 2025
Potentilla freyniana Bornm. and its active component Tangeretin ameliorate gouty arthritis by inhibiting the MAPK/NF-κB/NLRP3 signaling pathway.
(PubMed, J Ethnopharmacol)
- "The PFB aqueous extract and its active constituent Tangeretin alleviate gouty arthritis by suppressing the MAPK/NF-κB/NLRP3 signaling pathway."
Journal • Dermatology • Gout • Immunology • Inflammation • Inflammatory Arthritis • Rheumatology • IL18 • IL1B • NLRP3 • TNFA
December 11, 2025
Decoding colchicine: Applications and safety insights.
(PubMed, J Pak Med Assoc)
- No abstract available
Journal
December 11, 2025
Induction of Autopolyploidy and Preliminary Investigation of the Dwarfing Mechanism in Hedychium coccineum.
(PubMed, Plants (Basel))
- "In this study, Hedychium coccineum tetraploid plants and octaploid plants induced by colchicine were used as materials...Cytological and molecular evidence together indicate that HcPCNA1 may influence plant height in H. coccineum through its role in promoting cell division and elongation. This finding provides new insights into the molecular mechanisms underlying plant architecture development in polyploid species."
Journal • Endocrine Disorders • PCNA
December 11, 2025
A Case of Acute Pancreatitis Related to Therapeutic Dosing With Colchicine and Review of the Literature.
(PubMed, Am J Ther)
- No abstract available
Journal • Pancreatitis
December 03, 2023
B-Lymphoblastic Leukemia Presenting with Eosinophilia: A Case Report and Review
(ASH 2023)
- "Empiric steroids, colchicine, and intravenous immunoglobulin were initiated...The patient began induction therapy with aBFM, rituximab, PEG-asparaginase, and intrathecal cytarabine...As a result, therapy with blinatumomab was initiated...A significant proportion of cases of ALL with eosinophilia involve t(5; 14)(q31; q32), leading to overexpression of IL-3, which was not definitively found in this patient; however, there are numerous other recurrent abnormalities that may be contributing to the pathogenesis, both concurrently with and in the absence of this translocation, including other rearrangements of IGH as well as IKZF1 and CDKN2A abnormalities. Prompt diagnosis, now commonly using sensitive molecular diagnostic assays, and initiation of glucocorticoids for symptom control and subsequent antileukemic therapy, are essential to avoiding complications of eosinophilia in such patients."
Case report • Clinical • Review • Anemia • Eosinophilia • Hematological Disorders • Hematological Malignancies • Leukemia • Musculoskeletal Pain • Oncology • Pain • Thrombocytopenia • CD20 • CD34 • CD79A • CDKN2A • IKZF1 • KIT • MME • PAX5 • PTPRC
December 11, 2025
Early recurrence of atrial arrhythmia and healthcare utilization during the 8-week blanking period following thermal energy catheter ablation of atrial fibrillation.
(PubMed, Heart Rhythm)
- No abstract available
HEOR • Journal • Atrial Fibrillation • Cardiovascular
December 09, 2025
The olfactory epithelium as a gateway for bloodborne nanoparticles to the central nervous system.
(PubMed, Biomater Sci)
- "Pharmacological inhibition of axonal transport (colchicine, 10 μg μl-1) and chemical ablation of the OE (ZnCl2, 5%) completely blocked Mn3O4-NP accumulation in olfactory pathways (olfactory bulb, olfactory tract, and cortical targets), while permitting unaltered deposition in the adenohypophysis, confirming an olfactory neuron-dependent transport mechanism...These findings establish the OE as a dual-pathway hub for systemic NPs, facilitating CNS entry via intracellular axonal transport (Mn3O4-NPs) or paracellular mechanisms (LbL-Au). By demonstrating that blood-borne NPs can exploit olfactory pathways to bypass the BBB, this work challenges traditional models of CNS xenobiotic entry and opens new avenues for targeted neurotherapeutic delivery."
Journal
December 09, 2025
Henoch-Schönlein purpura induced by sitagliptin: A case report.
(PubMed, SAGE Open Med Case Rep)
- "Sitagliptin was discontinued, and the patient was treated with celecoxib, colchicine, and cefadroxil for wound infection. However, urinalysis revealed new 0.3 g/L protein. Overall, this case highlights a new potential association of dipeptidyl peptidase-4 inhibitors with Henoch-Schönlein purpura, which may have systemic consequences."
Journal • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • Vasculitis
December 09, 2025
Colchicine-Induced Severe Bone Marrow Suppression: Treatment With Platelet Suspensions.
(PubMed, Am J Ther)
- No abstract available
Journal
December 09, 2025
CogCAB-Pilot: Pilot Trial of Colchicine for Graft Failure in CABG
(clinicaltrials.gov)
- P4 | N=100 | Not yet recruiting | Sponsor: Ruijin Hospital | Trial completion date: Dec 2027 ➔ Dec 2028 | Initiation date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2027 ➔ Oct 2028
Trial completion date • Trial initiation date • Trial primary completion date
December 09, 2025
Anesthetic Management of a Dental Patient With Familial Mediterranean Fever.
(PubMed, Anesth Prog)
- "The patient had shown resistance to colchicine therapy in the past, necessitating careful consideration of alternative treatments, including the potential use of IL-1 inhibitors...Achieving safe anesthetic management for patients with FMF requires meticulous perioperative planning, proactive avoidance of potential FMF triggers, and a collaborative approach across disciplines. These elements are essential to preventing perioperative FMF exacerbations and ensuring smooth, complication-free recovery for patients."
Journal • Anesthesia • Genetic Disorders • Pain
December 08, 2025
Recurrent Pericarditis in a Patient With Ankylosing Spondylitis: A Report of a Rare Case.
(PubMed, Cureus)
- "We report a 31-year-old human leukocyte antigen B27 (HLA-B27)-positive man with AS diagnosed in 2018 who, after discontinuing golimumab in 2021, experienced two episodes of acute pericarditis in 2025...He improved with colchicine and a corticosteroid taper...Taken together, the relapse and overall context favored attribution to AS-related inflammation. This case underscores the need to keep pericarditis in mind when patients with AS present with chest pain and to align pericarditis therapy with control of the underlying disease."
Journal • Ankylosing Spondylitis • Cardiovascular • CNS Disorders • Cytomegalovirus Infection • Depression • Epstein-Barr Virus Infections • Hepatitis B • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Pain • Psychiatry • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies
December 08, 2025
Exploring the role of NOD2 variants in pediatric undifferentiated recurrent fever: a clinical and functional perspective.
(PubMed, Front Immunol)
- "All patients were treated with colchicine, and selected cases required corticosteroids or disease-modifying antirheumatic drugs...Certain variants, such as A1000T and P268S, appeared to show baseline NF-kB activation with moderate inflammatory activity. Our findings emphasize the clinical and functional diversity of NOD2 variants in SURF and may point to a possible genotype-phenotype relationship that could aid in understanding disease pathways and refining diagnostic approaches."
Journal • Inflammation • Musculoskeletal Pain • Pain • Pediatrics • CXCL8 • IL2 • TNFA
December 08, 2025
Atypical Pediatric-Onset Behçet's Disease Presenting With Superior Vena Cava Thrombosis in an Adolescent Male: A Case Report.
(PubMed, Clin Case Rep)
- "The patient was treated with corticosteroids, azathioprine, colchicine, and rivaroxaban, resulting in clinical and radiologic improvement. This case highlights a rare and aggressive vascular manifestation of Behçet's disease in an adolescent, emphasizing the need for early diagnosis and immunosuppressive management to prevent long-term complications."
Journal • Cardiovascular • Hematological Disorders • Pain • Pediatrics • Rare Diseases • Thrombosis • Vasculitis
December 08, 2025
Colchicine in coronary artery and cerebrovascular disease: "Old skin for the new ceremony".
(PubMed, World J Cardiol)
- "This result casts doubt on the indication for colchicine use in ACS and weakens evidence that had previously led to the routine use of colchicine in clinical cardiology practice. This review aims to shed light on the current and past scientific evidence underlying the use of colchicine in ACS, CCS and cerebrovascular disease, and thus seeks to provide a quick yet effective tool for cardiologists facing the long-standing issue of reducing residual inflammatory risk in patients with coronary atherosclerotic disease."
Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • CNS Disorders • Coronary Artery Disease • Genetic Disorders • Gout • Inflammation • Inflammatory Arthritis • Myocardial Infarction • Rare Diseases • Rheumatology • Vascular Neurology
December 06, 2025
Discovery of novel quinazoline analogs as tubulin inhibitors targeting the colchicine binding site for potent antitumor therapy in combination with PD-L1 inhibitors.
(PubMed, Bioorg Chem)
- "Compound 4a stood out as the most effective across four cancer cell, affording a mean IC50 value of 52 nM marginally superior to that of colchicine (IC50 = 59 nM), possessing the capacity to circumvent paclitaxel-associated drug resistance. Co-administration of 4a and NP19 (a PD-L1 blockade) led to a pronounced synergistic antitumor effect (TGI 85.20 %). In summary, 4a represents a candidate CBSIs for deeper study."
Journal • Oncology
December 06, 2025
Undifferentiated autoinflammatory diseases: a systematic review.
(PubMed, World J Pediatr)
- "A diagnosis of uAIDs should be considered in patients who present with autoinflammatory features, such as fever, arthralgia and abdominal pain and who do not meet the diagnostic criteria for monogenic or polygenic AIDs or other confounding conditions. The responsiveness to IL-1-targeted biologics implies that the IL-1 pathway may be a potential gateway in uAIDs. Future prospective studies with standardized criteria are needed to overcome current limitations of exclusion-based diagnosis and study heterogeneity in uAIDs research."
Journal • Review • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain
December 05, 2025
Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.
(PubMed, Reumatologia)
- "Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance...Interleukin-6 inhibitors (tocilizumab - TCZ) have been suggested to be potentially beneficial...Although the duration of follow-up of TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a good treatment option after IL-1 inhibitors and warrants further investigation."
Journal • Review • Amyloidosis • Genetic Disorders • Immunology • Musculoskeletal Pain • Pain • Renal Disease • Rheumatology • CRP • IL6
December 05, 2025
Repurposing the USFDA-approved small molecules for their affinity against the colchicine binding site (CBS) in the tubulin: Corroborating the in-silico findings through biological assessment.
(PubMed, Bioorg Med Chem)
- "Tafenoquine was found to exert broad-spectrum antiproliferative effects, with greatest potency against MDA-MB-231 cells (IC₅₀ = 4.75 ± 0.18 μM), a model for aggressive and treatment-resistant triple-negative breast cancer (TNBC). Considering the tubulin polymerization assay, the identified hit was found to inhibit microtubule assembly (low Vmax) in a manner similar to colchicine, and exhibited a similar G2/M arrest, indicating a mode of inhibition similar to that of colchicine."
FDA event • Journal • Breast Cancer • Colon Cancer • Infectious Disease • Oncology • Solid Tumor • Triple Negative Breast Cancer
1 to 25
Of
6919
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277